TNF and Sepsis: Preclinical studies have shown that agents such as infliximab (anti–TNF-α monoclonal antibody) and tocilizumab (IL-6 receptor antagonist) can reduce tissue injury and improve survival in models of sepsis-induced lung and kidney injury [148].